Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sympathetic Mechanisms in Obesity-Associated Insulin Resistance
NCT04329806Phase 1Terminated
- Start
- Feb 2021
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 1, randomised trial of moxonidine in insulin resistance (IR) and hypertension (HTN) (2 arms). Primary endpoint: Insulin Sensitivity at 6 hours. Started Feb 2021; status: terminated.
02
Drugs
moxonidine
03
Conditions
insulin resistance (IR)hypertension (HTN)
Beyond the preview
Go deeper on NCT04329806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04329806.